Allen Williamson, DO
Family Medicine · Port Arthur, TXNPI 1548269566
Payments from drug & device makers
Across 345 payments — averaging $17.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$1K
- Pfizer$397
- Bayer$391
- AstraZeneca$348
- Sanofi-aventis U.S. LLC$344
- plus $2K from 33 others
What the payments were for
- Food & beverage$6,074100%
- Education$200%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 91 | $1,259 |
| Novo Nordisk | 72 | $1,021 |
| Pfizer | 19 | $397 |
| Bayer | 21 | $391 |
| AstraZeneca | 15 | $348 |
| Sanofi-aventis U.S. LLC | 9 | $344 |
| Amarin Pharma, Inc. | 17 | $335 |
| Lilly USA, LLC | 18 | $281 |
| GSK | 11 | $196 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $180 |
| Smith+Nephew | 2 | $138 |
| Dexcom, Inc. | 4 | $137 |
| Novartis | 7 | $127 |
| Johnson & Johnson | 4 | $98 |
| Esperion Therapeutics, Inc. | 4 | $73 |
| Boehringer Ingelheim | 4 | $73 |
| Kowa Pharmaceuticals America, Inc. | 3 | $65 |
| Arbor Pharmaceuticals, Inc. | 4 | $64 |
| Merck | 4 | $57 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $57 |
| Regeneron Healthcare Solutions, Inc. | 1 | $49 |
| Ironwood Pharmaceuticals, Inc | 3 | $40 |
| Shire North American Group Inc | 2 | $36 |
| Astellas Pharma US Inc | 2 | $34 |
| Exact Sciences | 2 | $33 |
| Amgen | 2 | $32 |
| Radius Health, Inc. | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Boston Scientific | 1 | $22 |
| Nevro Corp. | 1 | $21 |
| Sumitomo Pharma America, Inc. | 1 | $21 |
| Idorsia Pharmaceuticals US Inc | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Genentech USA, Inc. | 1 | $17 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Eisai Inc. | 1 | $13 |
| Optos, Inc. | 2 | $12 |
| IBSA Pharma Inc. | 1 | $12 |
| Philips North America LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,094 in reported general payments places this provider in the 85th percentile of 8,760 family medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 128 | $173,747 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 80 | $77,673 |
| EliquisApixaban | 54 | $38,557 |
| FarxigaDapagliflozin Propanediol | 35 | $36,713 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $29,092 |
| TrulicityDulaglutide | 15 | $27,553 |
| RybelsusSemaglutide | 16 | $26,552 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $24,970 |
| JardianceEmpagliflozin | 17 | $23,068 |
| JanuviaSitagliptin Phosphate | 18 | $21,398 |
| XareltoRivaroxaban | 23 | $20,394 |
| VraylarCariprazine Hcl | 12 | $18,411 |
| MounjaroTirzepatide | 17 | $18,120 |
| LinzessLinaclotide | 11 | $14,190 |
| JanumetSitagliptin Phos/Metformin Hcl | 13 | $11,783 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,021 | $200,299144 claims |
| GSKTrelegy Ellipta | $196 | $77,67380 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $281 | $45,67332 claims |
| PfizerEliquis | $397 | $38,55754 claims |
| AstraZenecaFarxiga | $348 | $36,71335 claims |
| AbbVieVraylar, Linzess, Synthroid | $1,259 | $34,75886 claims |
| MerckJanuvia, Janumet | $57 | $33,18131 claims |
| Boehringer IngelheimJardiance | $73 | $23,06817 claims |
| Johnson & JohnsonXarelto | $98 | $20,39423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Port Arthur
- Douglas DenhamSan Antonio$68.5M
- Vicki MillerPasadena$58.3M
- Hareshkumar BogharaDesoto$30.3M
- Earl MartinTomball$30.1M
- Lisa HollowayHouston$30.1M
- William SegerFort Worth$27.5M
- Veronica FragosoHouston$24.5M
- Joel SolisMcAllen$21.1M
- George AtieeSan Antonio$19.9M
- Bonnie ColvilleHouston$19.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.